How long does paxlovid take to work
Pro Research Analysisby 
Searched over 200M research papers
How Long Does Paxlovid Take to Work?
Paxlovid Effectiveness in Reducing Hospitalization and Death
Paxlovid, an antiviral medication developed by Pfizer, has shown significant effectiveness in reducing the risk of hospitalization and death in COVID-19 patients. In a study where participants were treated within three days of symptom onset, only 0.8% of those who received Paxlovid were admitted to the hospital, with no deaths reported. In contrast, 7% of the placebo group were hospitalized, and seven deaths occurred, indicating a high statistical significance (P<0.0001) .
Timing of Paxlovid Administration
Early Administration Within Five Days
The timing of Paxlovid administration is crucial for its effectiveness. A study involving patients with chronic kidney disease (CKD) found that those who received Paxlovid within five days of diagnosis had significantly better outcomes. These patients experienced shorter hospital stays and lower rehospitalization rates compared to those who received the drug after five days. Specifically, early administration resulted in a shorter duration of positive PCR tests (7 days vs. 25 days) and reduced hospital stays (10 days vs. 16 days) .
Delayed Administration After Five Days
Conversely, patients who received Paxlovid after five days of diagnosis had longer hospital stays and higher rehospitalization rates. The delayed administration was associated with prolonged nucleic acid positivity and extended hospital stays, highlighting the importance of early intervention .
Paxlovid in Pediatric Patients
In pediatric patients with hematological diseases infected with the Omicron variant of SARS-CoV-2, Paxlovid also demonstrated effectiveness. Children treated with Paxlovid had a shorter duration of fever (1-6 days) compared to those who did not receive the drug (0-3 days). Additionally, the viral clearance time was shorter in the Paxlovid group, indicating quicker recovery .
Conclusion
Paxlovid is highly effective in reducing hospitalization and death in COVID-19 patients, particularly when administered within five days of symptom onset. Early administration leads to shorter hospital stays, quicker viral clearance, and better overall outcomes. Delayed use, however, can result in prolonged illness and increased hospital stays. Therefore, timely administration of Paxlovid is critical for maximizing its therapeutic benefits.
Sources and full results
Most relevant research papers on this topic
Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports
Paxlovid is 89% effective in reducing hospital admissions and deaths in Covid-19 patients, with no deaths observed in the study.
#5505 EFFICACY OF PAXLOVID WITHIN 5 DAYS VERSUS 5 DAYS AFTER DIAGNOSIS IN COVID-19 PATIENTS WITH CHRONIC KIDNEY DISEASE
Paxlovid is effective in COVID-19 patients with chronic kidney disease, but its use within 5 days of diagnosis is associated with more severe disease and increased use of glucocorticoids.
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Paxlovid effectively reduces the risk of severe COVID-19 or mortality in high-risk patients, with greater effectiveness in older, immunosuppressed, and patients with underlying neurological or cardiovascular diseases.
DOI